Effect of gender on results of percutaneous edge-to-edge mitral valve repair with MitraClip system
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effect of gender on results of percutaneous edge-to-edge mitral valve repair with MitraClip system. / Estévez-Loureiro, Rodrigo; Settergren, Magnus; Winter, Reidar; Jacobsen, Per; Dall'Ara, Gianni; Sondergaard, Lars; Cheung, Gary; Pighi, Michele; Ghione, Matteo; Ihlemann, Nikolaj; Moat, Neil E; Price, Susanna; Streit Rosenberg, Tine; Di Mario, Carlo; Franzen, Olaf.
I: American Journal of Cardiology, Bind 116, Nr. 2, 15.07.2015, s. 275-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of gender on results of percutaneous edge-to-edge mitral valve repair with MitraClip system
AU - Estévez-Loureiro, Rodrigo
AU - Settergren, Magnus
AU - Winter, Reidar
AU - Jacobsen, Per
AU - Dall'Ara, Gianni
AU - Sondergaard, Lars
AU - Cheung, Gary
AU - Pighi, Michele
AU - Ghione, Matteo
AU - Ihlemann, Nikolaj
AU - Moat, Neil E
AU - Price, Susanna
AU - Streit Rosenberg, Tine
AU - Di Mario, Carlo
AU - Franzen, Olaf
N1 - Copyright © 2015 Elsevier Inc. All rights reserved.
PY - 2015/7/15
Y1 - 2015/7/15
N2 - Knowledge regarding gender-specific results of percutaneous edge-to-edge mitral valve repair is scarce. The aim of this study was to investigate gender differences in outcomes in a cohort of patients treated with MitraClip implantation. A multicenter registry of 173 patients treated with MitraClip prostheses from 2009 to 2012 at 3 experienced centers was performed. One hundred nine patients (63%) were men. Men were younger (mean age 73 ± 10 vs 79 ± 9 years, p = 0.001) and had a higher prevalence of previous coronary bypass graft surgery (34% vs 13%, p = 0.002), previous myocardial infarction (46% vs 20%, p = 0.001), and diabetes mellitus (26% vs 11%, p = 0.020). There were no differences regarding New York Heart Association (NYHA) functional class before the intervention (NYHA class III or IV in 95% of men vs 97% of women, p = 0.472) or the cause of mitral regurgitation (MR) (functional in 58% of men vs 48% of women, p = 0.233). Men exhibited significantly larger ventricles (mean indexed left ventricular end-systolic diameter 2.4 ± 0.8 vs 2.0 ± 1.6 cm/m(2), p = 0.002, and mean indexed left ventricular end-diastolic volume 92.7 ± 46.1 vs 59.9 ± 24.6 ml/m(2), p <0.001). At 1 month, there were no differences between groups in the reduction of MR or NYHA functional class (MR grade ≤2+ in 98.2% of men vs 96.8% of women, p = 0.586, and NYHA class ≤II in 78.3% of men vs 77% of women, p = 0.851). At 6 months, results were maintained (MR grade ≤2+ in 89.5% of men vs 96.8% of women, p = 0.414, and NYHA class ≤II in 73.1% of men vs 74.2% of women, p = 0.912). After a mean follow-up period of 16.1 ± 11.1 months, no difference was found between groups in the incidence of death or admission for heart failure (log-rank p = 0.798). In conclusion, MitraClip implantation seems to be an equally safe and effective treatment of MR in men and women.
AB - Knowledge regarding gender-specific results of percutaneous edge-to-edge mitral valve repair is scarce. The aim of this study was to investigate gender differences in outcomes in a cohort of patients treated with MitraClip implantation. A multicenter registry of 173 patients treated with MitraClip prostheses from 2009 to 2012 at 3 experienced centers was performed. One hundred nine patients (63%) were men. Men were younger (mean age 73 ± 10 vs 79 ± 9 years, p = 0.001) and had a higher prevalence of previous coronary bypass graft surgery (34% vs 13%, p = 0.002), previous myocardial infarction (46% vs 20%, p = 0.001), and diabetes mellitus (26% vs 11%, p = 0.020). There were no differences regarding New York Heart Association (NYHA) functional class before the intervention (NYHA class III or IV in 95% of men vs 97% of women, p = 0.472) or the cause of mitral regurgitation (MR) (functional in 58% of men vs 48% of women, p = 0.233). Men exhibited significantly larger ventricles (mean indexed left ventricular end-systolic diameter 2.4 ± 0.8 vs 2.0 ± 1.6 cm/m(2), p = 0.002, and mean indexed left ventricular end-diastolic volume 92.7 ± 46.1 vs 59.9 ± 24.6 ml/m(2), p <0.001). At 1 month, there were no differences between groups in the reduction of MR or NYHA functional class (MR grade ≤2+ in 98.2% of men vs 96.8% of women, p = 0.586, and NYHA class ≤II in 78.3% of men vs 77% of women, p = 0.851). At 6 months, results were maintained (MR grade ≤2+ in 89.5% of men vs 96.8% of women, p = 0.414, and NYHA class ≤II in 73.1% of men vs 74.2% of women, p = 0.912). After a mean follow-up period of 16.1 ± 11.1 months, no difference was found between groups in the incidence of death or admission for heart failure (log-rank p = 0.798). In conclusion, MitraClip implantation seems to be an equally safe and effective treatment of MR in men and women.
KW - Aged
KW - Denmark
KW - Female
KW - Follow-Up Studies
KW - Great Britain
KW - Heart Valve Prosthesis
KW - Humans
KW - Incidence
KW - Kaplan-Meier Estimate
KW - Male
KW - Mitral Valve Insufficiency
KW - Postoperative Complications
KW - Prosthesis Design
KW - Retrospective Studies
KW - Sex Factors
KW - Survival Rate
KW - Sweden
KW - Treatment Outcome
U2 - 10.1016/j.amjcard.2015.04.019
DO - 10.1016/j.amjcard.2015.04.019
M3 - Journal article
C2 - 25960377
VL - 116
SP - 275
EP - 279
JO - Am. J. Cardiol.
JF - Am. J. Cardiol.
SN - 0002-9149
IS - 2
ER -
ID: 162597569